Generate Biomedicines (GENB) director Parker received 29,561 Stock Option (Right to Buy)
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Paul Gray Parker (director at Generate Biomedicines Inc., GENB) reported that they received 29,561 Stock Option (Right to Buy) on Feb 26, 2026.
- Reporting person
- Parker Paul Gray
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Feb 26, 2026 | Grant or award (A) | Stock Option (Right to Buy)On 29,561 Common Stock1 | +29,561 | - | - | 29,561 direct |
Holdings before and after
- Stock Option (Right to Buy): 0 to 29,561 direct
Footnotes from the filing
- 1. The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Parker report in this GENB Form 4?
Paul Gray Parker (director at Generate Biomedicines Inc., GENB) reported that they received 29,561 Stock Option (Right to Buy) on Feb 26, 2026.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for GENB
Earlier insider filings at GENB
Keep researching GENB
- GENB insider tradesEvery buy and sale reported by Generate Biomedicines Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- GENB dividend historyDividends Generate Biomedicines Inc. has declared, with ex-dates and payment dates.
Quantisnow market dataNASDAQ
GENB
Generate Biomedicines Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2026
Get push alerts for GENB
Full GENB profile on Quantisnow Follow GENB and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time